Two patients with Philadelphia-positive chronic myelogenous leukemia underwent allogeneic bone marrow transplantation from a related HLA mismatched donor (patient 1) or from an unrelated HLA-identical donor (patient 2). Following bone marrow transplantation partial engraftment (patient 1) or graft failure (patient 2) occurred followed by autologous Philadelphia negative hematopoietic recovery either spontaneously (patient 1) or after infusion of autologous bone marrow rescue (patient 2). Neither Philadelphia chromosome, nor bcr-abl rearrangement was detectable by PCR analysis up to 7 years (patient 1) and 9 years (patient 2) post-transplantation. These two observations indicate that sustained engraftment of allogeneic bone marrow stem cells following a myeloablative regimen is not necessary to cure chronic myelogenous leukemia. It is hypothesized that the proliferative advantage of Philadelphia-negative progenitors and the anti-leukemic effect of lymphocytes in the graft have resulted in prolonged remission of the patients. Keywords: bone marrow transplantation; chronic myelogenous leukemia; graft failure; endogenous recovery; remission Allogeneic bone marrow transplantation (BMT) with an HLA-identical related donor remains the best curative treatment for patients with Philadelphia positive (Ph+) chronic myelocytic leukemia (CML), allowing a disease-free survival (DFS) of 60% at 5 years when patients are transplanted in first chronic phase.
Allogeneic bone marrow transplantation (BMT) with an HLA-identical related donor remains the best curative treatment for patients with Philadelphia positive (Ph+) chronic myelocytic leukemia (CML), allowing a disease-free survival (DFS) of 60% at 5 years when patients are transplanted in first chronic phase. 1 For patients who lack a sibling-related donor, various treatment modalities including alpha interferon (IFN), 2 autologous stem cell transplantation 3, 4 and allogeneic BMT from an unrelated donor, 5 have been shown to improve DFS. We report two Ph+ CML patients in whom failure of allogeneic bone marrow engraftment was followed by autologous Philadelphia negative (Ph−) hematopoietic recovery; either spontaneously or after infusion of autologous bone marrow for rescue. Seven years (patient 1) and 9 years (patient 2) post-allogeneic BMT these two patients remain in hematological, cytogenetic and molecular remission of CML with autologous hematopoiesis. These observations suggest that sustained engraftment of allogeneic bone marrow stem cells following a myeloablative regimen may not be necessary to cure chronic myelogenous leukemia. The combination of the ablative pre-transplant regimen, the anti-leukemic effect of allogeneic lymphocytes in the graft and the proliferative advantage of Philadelphia-negative progenitors over leukemic progenitors, possibly explain the prolonged remission obtained in these two patients.
Case reports

Patient 1
A 20-year-old male patient, in first chronic phase Ph+ CML, had an allogeneic BMT from an HLA-matched MLC negative unrelated male donor in July 1989. A total number of 1.62 × 10 8 /kg of body weight allogeneic nucleated cells was infused without T cell depletion. Conditioning comprised cyclophosphamide (120 mg/kg) and fractionated total body irradiation (TBI) (12 Gy, six fractions). Graftversus-host disease (GVHD) prophylaxis was with cyclosporin A and methotrexate. Recovery of hematopoiesis was achieved on day 22 for neutrophils (Ͼ0.5 × 10 9 /l), day 27 for leucocytes (Ͼ10 /l were reached on day 44 post-alloBMT or day 15 post-auto BMT. No growth factor was added. Interferon therapy was started on day 60 post-alloBMT or day 30 post-autoBMT at a dose of 5 million units per day for 6 months, and 5 million units three times a week for 3 more months, then stopped. The Philadelphia chromosome was undetectable 2 months postalloBMT immediately before interferon therapy was started, and remained undetectable 10 months and 1 year post-alloBMT. Bcr-abl rearrangement analyzed by PCR was also negative.
Seven years later, the patient was alive and well in hematological and molecular remission of CML as assessed by nested PCR. Cytogenetic analysis of both bone marrow and blood cells did not show the Philadelphia chromosome. However, cytogenetic analysis of both bone marrow cells and fibroblasts revealed the presence of non-clonal abnormalities such as structural changes indicative of chromosomal instability. Donor cells remained undetectable and PCR analysis confirmed persistence of autologous hematopoiesis (Figure 2 ). This situation is unchanged 9 years post-BMT.
Discussion
We report two patients with Ph+ CML, who, after allogeneic BMT performed with an HLA-matched unrelated donor (patient 1) or an HLA-mismatched related donor (patient 2), developed graft failure and then experienced full long-term autologous hematopoietic recovery with hematological, cytogenetic and molecular complete remission of CML.
Ph+ CML marrow contains Ph− cells which can be collected from the peripheral blood during early recovery after chemotherapy-induced marrow aplasia; these cells contain very primitive hematopoietic progenitors defined as longterm culture initiating cells (LTCIC), 7 and are capable of restoring hemopoiesis when autografted in CML patients. 8 Autologous bone marrow or peripheral blood stem cell transplantation carried out in chronic phase CML with infusion of predominantly Ph-positive unmanipulated stem cells has been reported in a few instances as giving rise to cytogenetic remission with disappearance of Ph+ metaphasis;
9-12 major cytogenetic response is usually associated with longer survival; however regained Ph− hemopoiesis is not usually sustained beyond 6 months. 3 Interestingly, it has been suggested that the polyclonal hemopoiesis observed after autografting with peripheral blood mobilized by chemotherapy and granulocyte colony-simulating factor originates not only from autografted stem cells but also from recruitment of endogenous normal stem cells which have survived the conditioning regimen. 13 In long-term marrow culture, the dominant Ph+ population rapidly disappears, in contrast to the coexisting chromosomally normal Ph− hematopoietic progenitors; these progenitors may have a proliferative advantage over clonal Ph+ hematopoiesis after transplantation.
14 A variety of studies have shown that at least some of these Ph− hematopoietic cells do not belong to the leukemic clone and are presumably normal. Autografts of cultured marrow have resulted in prolonged restoration of Ph− hematopoiesis. 15 Interferon therapy is nowadays the first-line treatment of CML in first chronic phase and is associated with about 25% complete cytogenetic remissions; however the disappearance of bcr-abl translocation following interferon, although reported, is infrequent. Longer survival is associated with cytogenetic responses lasting more than 12 months. 16 In 1982 Branch et al 17 reported that following TBI and allogeneic marrow transplantation for acute leukemia, endogenous stem cell repopulation could occur resulting in mixed hematopoietic chimerism. Complete autologous recovery of hematopoiesis was reported in 1991 in a young patient with juvenile CML treated with granulocyte-monocyte colony-stimulating factor and interleukin-3 after graft failure of a matched unrelated allogeneic transplant. 18 More recently, spontaneous hematopoietic recovery was reported after exposure to more than 10 Gy in a radiation accident in a victim treated with hematopoietic growth factors without stem cell transplantation, even though damage of hematopoietic stem cells after ionizing radiation exceeding 8 Gy is usually considered as irreversible and hematopoietic recovery only possible after a bone marrow transplant. 19 These observations show that myeloblative conditioning regimens do not always entirely destroy the endogenous long-term repopulating normal stem cell pool.
The anti-leukemic effect of lymphocytes in an allograft is well established; in humans, the contribution of the graftversus-leukemia (GVL) reaction to the cure of patients has been documented: relapse rates are significantly higher after T cell depletion of donor bone marrow. 20 Patients with GVHD have fewer relapses than patients without GVHD. As described recently, donor lymphocyte infusions can induce durable remissions in CML relapsing after allogeneic BMT. 21, 22 Induction of a GVL effect by the combination of interferon alfa-2b and infusion of donor mononuclear cells is an effective anti-leukemic therapy in patients with CML who relapse after bone marrow transplantation. 23 In patient 1 of the present report, autologous Ph− normal stem cells surviving the conditioning regimen which included TBI allowed normal Ph− long-term hematopoietic recovery, while the Ph+ clone was reduced by the conditioning regimen. The residual leukemic clone persisting after the conditioning therapy may have been controlled by the GVL effect possibly combined with a proliferative advantage of Ph− hematopoietic progenitors, leading to long-term remission. No residual tumor cells were detectable by PCR analysis, a technique which allows detection of one abnormal cell in 10 5 normal cells. 24 A similar observation was reported by Kolb et al: 25 a male patient with accelerated phase CML was transplanted with marrow from an HLA-identical sister, and developed severe acute and chronic GVHD and severe pneumonia. He then had evidence of a transient high proportion of male Ph− metaphases before a return to complete chimerism. This observation suggested that normal hematopoietic stem cells may survive intensive chemotherapy, bone marrow transplantation and the chronic GVHD reaction, and that CML may be eliminated by the GVH reaction that recognizes recruited cells and spares dormant cells. 25 The situation was different in patient 2 who received an autologous transplant as rescue for graft failure post-allogeneic BMT. The autograft was presumably Ph+ since cytogenetic analysis performed 1 month before harvest from bone marrow showed the Philadelphia chromosome to be present in 100% of cells, and no interferon therapy was started. The myeloablative regimen and proliferative advantage of the normal progenitors may not be the only explantation for the 9 year remission. In fact, post-transplant interferon therapy and a possible GVL effect induced by the residual T cells persisting after T cell depletion of the allograft may have participated.
These two observations show that long-term autologous Philadelphia-negative hematopoiesis (7 and 9 years) can be observed in Ph+ CML patients after graft failure of allogeneic BMT. It is suggested that sustained allogeneic engraftment is not absolutely necessary to cure CML and that Ph+ stem cells may be destroyed by allotransplants without eliminating normal host hematopoiesis.
